EU Clinical Trial 2019-000843-29

Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year, Randomized, Multi-Center, Open-Label, Parallel-Group, Active Treatment Controlled, Dose Selection Trial  May 31, 2019

Main objective of the trial: Assess the efficacy and safety of three combinations of rhGH and rhIGF-1 compared to that of rhGH alone in the treatment of short stature associated with IGF-1 deficiency

Parties

Sponsors
Countries
EU US
Keywords
Increlex® Mecasermin Nutropin AQ Somatropin

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.